Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,333 Cr
verified against source
Revenue YoY
18%
reported change
EBITDA
₹1,088 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a strong Q3 FY26 with 18% revenue growth to ₹3,333 crore and 19% EBITDA growth to ₹1,088 crore, driven by double-digit expansion in India (+14%) and Brazil (+27% reported, +10% constant currency). The US business grew 19% (12% constant currency) to $36 million, while Germany declined 6% constant currency due to a third-party supplier disruption. The JB Pharma acquisition (48.8% stake) closed in January, with cost synergies of ₹400-450 crore targeted over 2-3 years, though Q4 may see a muted impact from integration. Management expects India to continue outperforming the IPM, and US sales to cross $200 million annually next year. Key risk: Germany supply disruption remains unresolved, with no clear timeline for resolution.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects India revenue growth to remain above the IPM growth rate, driven by volume outperformance in chronic therapies.
- Management targets US annual revenue exceeding $200 million in FY27, driven by 5-7 new launches per year.
- Cost synergies from JB acquisition expected to be ₹400-450 crore, with ~20% in first year, up to 80% in second year, and rest in third.
- Brazil business expected to grow 10-15% driven by new product launches and moderate price increases.
Risks flagged
- Third-party supplier disruption continues with no clear timeline for resolution; alternative supplier may take 3-4 quarters.
- Management expects Q4 to be muted due to change of control and process integration, potentially impacting sales.
- Semaglutide launch delayed to next financial year; regulatory approval timeline uncertain despite prioritization.
- US revenue growth is contingent on timely new launches and competitive landscape, which are unpredictable.
Key quotes
- Our two largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%.
- Our synergy number is looking like 400 to 450 crores over the next 2 to 3 years. Maybe 20% of that could be in the first year, up to 80% of that could be in the second year and the rest in the third year.
- I would guide towards a higher sales number from where we are and I would guide towards at least five to seven launches a year.
Research modules